Source: Dubai – Arabic.net
Good news for the US President Donald Trump, who announced it would happen Medicine “Ramsdevir” On the green light to cure a corona. The US Food and Drug Administration (FDA) has authorized the manufacturer, Gilead Sciences, the emergency use of its experimental antiviral treatment to treat people with Covid-19 disease.
The drug provided a ray of hope in the fight against SK this week when the results of a promising clinical trial were released. The Cleveland Medical Center announced that the drug had proven effective in controlling the virus, and had succeeded in reducing the recovery time to 4 days.
Meanwhile, the manufacturer has pledged to “provide adequate supplies for patients worldwide.”
What is Ramdesiver and why was it developed?
It is an experimental antiviral drug that was first developed by the American drug company Gilliad Sciences for the treatment of Ebola.
Developed in 2015, Ramsdivir demonstrated early promises in an animal study and was later released in the Congo, but ultimately failed as an effective treatment for Ebola.
Speaking to the New York Post, the former assistant commissioner for the Food and Drug Administration, Peter Bates, said: “He never made a promise. He failed relatively against Ebola. So, doctors said let’s see if he works against Covid-19.”
How effective is it against corona?
The results of a clinical trial conducted on more than a thousand people showed that Covid-19 patients with respiratory problems improved by 31% faster than those who took the placebo, according to the National Institute of Allergy and Infectious Diseases.
However, Bates cautioned that the drug showed benefit only in patients who were hospitalized, the elderly, and those with respiratory or previous health problems. He said: “It saves lives but it does not change the rules of the game. Clinical trials have shown that it has led to recovery in 4-10% of patients with severe disease.”
How it works?
To get the job done, the drug simulates adenosine, one of the four building blocks of viral RNA – also known as RNA, and when the virus integrates Ramsdevir into its genome instead of adenosine, it becomes unable to reproduce, according to Agence France-Presse.
As Bates explains: “It enters itself into the viral RNA, and causes the virus to terminate prematurely.”
According to the results of the most recent study published by Gilliad Sciences, the most common adverse reactions were nausea and acute respiratory failure. About 7% of patients experienced a rise in liver enzymes.
How much will it cost?
This is still unclear, although CEO of Gilliad Sciences, Daniel Oday, told Stat News this week that the company is donating 1.5 million doses of the drug – about 140,000 courses of treatment – to hospitals.
Odai added that the company pledged “to work with the government and health care systems, to ensure access to the drug, and to make it accessible to governments in the future.”
Doctors say they need to know more about it. Some experts also consider it “a good guide” that could pave the way for better treatments.
“Clinical trials have shown a very positive effect on those hospitalized. But for the time being, it’s still an experimental drug,” said Peter Bates, a former assistant commissioner for the Food and Drug Administration.
It is noteworthy that besides “Hydroxychloroquine”, “Ramsdevir” is one of the options currently offered with a group of antiviral drugs.
However, the US Food and Drug Administration, the European Union’s Medicines Control Authority, the Canadian Health Service and the French Medicines Agency have recently warned against using “hydroxychloroquine”, pointing to side effects including a serious heartbeat and a rapid acceleration.